IP Library Granted Patent US 10,072,272
Granted Patent B2
US 10,072,272 · App. 14/551,487 · Granted Sep 11, 2018

Turkey herpesvirus vectored recombinant containing avian influenza genes

Inventors: Motoyuki Esaki (Lenexa, KS); Lauren Elizabeth Jensen (Kansas City, MO); Kristi M. Dorsey (Chadds Ford, PA)
Assignee: BIOMUNE COMPANY
C12N15/86A61K39/12A61K39/145C07K14/005C07K14/11C12N7/00C12N15/63C12N15/85C12N15/869A61K2039/5256C12N2710/16143C12N2710/16334C12N2710/16343C12N2710/16443C12N2760/16134C12N2830/34C12N2830/60
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,072,272
App. No.
14/551,487
Granted
Sep 11, 2018
Kind
B2
Abstract

The present invention provides a recombinant turkey herpesvirus modified by the presence of the cDNA encoding the hemagglutinin protein of avian influenza virus under a promoter. A poultry vaccine comprising the recombinant turkey herpesvirus described in the present invention can induce serological responses that may be easily detected by the hemagglutination inhibition assay but not by commercially available diagnostic ELISA kits; thus enabling easy differentiation between vaccination and field infection.

Claims (7)

1. A recombinant turkey herpesvirus comprising a hemagglutinin gene of avian influenza virus and a cytomegalovirus immediate early promoter, wherein said hemagglutinin (HA) gene is under control of said cytomegalovirus immediate early promoter, and wherein said HA gene is obtained from an H7 subtype of avian influenza virus.

2. The recombinant turkey herpesvirus according to claim 1 , wherein said hemagglutinin gene and said cytomegalovirus immediate early promoter are present in a non-essential region of the turkey herpesvirus genome.

3. The recombinant turkey herpesvirus according to claim 2 , wherein said non-essential region is between UL45 and UL46 of the turkey herpesvirus genome.

4. A poultry vaccine comprising the recombinant turkey herpesvirus according to claim 1 .

5. The poultry vaccine according to claim 4 , said vaccine further comprising a non-recombinant virus.

6. The poultry vaccine according to claim 5 , wherein said non-recombinant virus is a serotype 1 Marek's disease virus (MDV).

7. The poultry vaccine according to claim 5 , wherein said non-recombinant virus is a serotype 2 Marek's disease virus (MDV).

Assignments (4)
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Jan 2, 2024
From: CEVA ANIMAL HEALTH, LLC; BIOMUNE COMPANY; THUNDERSHIRT, LLC
To: NATIXIS, AS SECURITY AGENT
Reel/Frame 066163/0711 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY PREVIOUSLY RECORDED ON REEL 037748 FRAME 0435. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ENTIRE INTEREST. Recorded Apr 10, 2017
From: ZEON CORPORATION
To: BIOMUNE COMPANY
Reel/Frame 042247/0117 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 17, 2016
From: ESAKI, MOTOYUKI; JENSEN, LAUREN ELIZABETH; DORSEY, KRISTI M.
To: ZEON CORPORATION
Reel/Frame 037748/0433 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 17, 2016
From: ZEON CORPORATION
To: CEVA BIOMUNE
Reel/Frame 037748/0435 →
Continuity (4)
Division 12449037
Continuation In Part 11729978 · Mar 30, 2007
Related Publication 20150110835A1 · Apr 23, 2015
Related Publication 20170298386A9 · Oct 19, 2017